Xolair 150 MG/1.2 ML powder VLS
Ended Awarded Last action
- Contract number
- SPE2DR26FHCB1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $31,584
Award facts
- Contract value 100% obligated
- $31,584.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $31,584.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/1.2 ml powder vials. This firm fixed-price delivery order, issued on November 25, 2025, with an ultimate completion date of December 17, 2025, carries no set-aside designation, indicating the award was made through open competition. The delivery order falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group has demonstrated consistent performance as a critical supplier within the federal pharmaceutical supply chain, having secured its PPV-G GEN V prime vendor contract on November 13, 2025, with a $499.99 billion ceiling value and completion date of December 31, 2036. The contract encompasses a 30-month base period with three 30-month option periods and authorizes the issuance of firm fixed-price delivery orders for branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and medical consumables to support military healthcare facilities globally. As a woman-owned small business registered in the System for Award Management since 2001, DMS Pharmaceutical Group competes effectively in federal procurement while maintaining performance across diverse therapeutic categories, positioning it as a key regional pharmaceutical supplier for DoD medical operations.
Quick answers
Who was awarded contract SPE2DR26FHCB1?
SPE2DR26FHCB1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 25, 2025.
How much is contract SPE2DR26FHCB1 worth?
The government has obligated $31,584 on SPE2DR26FHCB1.
Is contract SPE2DR26FHCB1 an order under another contract?
Yes. SPE2DR26FHCB1 is a delivery order under SPE2DR25D9205, an indefinite delivery contract.
Was contract SPE2DR26FHCB1 competed?
The extent of competition for SPE2DR26FHCB1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award